Новости

Мы предлагаем Клиентам и Партнерам получить последнюю информацию о компании ARS и узнать об избранных новостях из сферы разработок фармацевтических и биологических препаратов, а также запланировать встречу на конференции с представителями ARS с целью детально в личной беседе обсудить потенциальные и текущие проекты.

09.02.2018
ARS Won a Tender

ARS PharmRussia gets a new Client that is one of the top biopharmaceutical companies worldwide. ARS team won a tender to conduct a bioequivalence study of an oncology generic drug in Russia. This will be the first project with this Partner.

15.01.2018
Regulatory Chances

ARS reveals the current challenges and opportunities of a foreign drug registration in Russia. The article posted should be very helpful for the overseas drug developers and manufactures.

24.12.2017
Happy NY 2018

ARS congratulates its Partners with the upcoming holidays and wishes all prosperity and good luck in 2018. 

15.12.2017
A New Client

ARS starts collaboration with one of the leading pharmaceutical companies from the Middle East. ARS hopes the first bioequivalence clinical study project is just the start of the long-term strategic partnership. 

10.11.2017
New Phase III study

ARS signed a contract with an Asian Sponsor to conduct a Phase III efficacy and safety clinical study in patients with stomatitis and gingivitis in Russia. ARS will be responsible for the drug’s registration as well. 

30.10.2017
CPhI Worldwide 2017

In October 2017, ARS business development director and CEO participated in the biggest pharmaceutical industry event devoted to generics and bio-analogues. 

15.10.2017
Drugs MAs & Renewals

Since April through September 2017, ARS registered a number of generic drugs (Montelukast, Nitrofurantoin, Tranexamic Acid, Torasemide, Dorzolamide, Iohexol, Clopidogrel, etc.) as well as successfully did several renewals (Simvastatin, Glucosamine + Chondroitin Sulphate + Vitamin E, Moxifloxacin, Lisinopril, Temozolomide, Piperacillin + Tazobactam, Clarithromycin, Ceftazidime, and Perindopril) for Indian, Pakistani, Russian, and UK pharmaceutical companies.

04.09.2017
Drugs & Nutrition

ARS signed an agreement for marketing authorization of Italian dietary supplements as well as medicines to treat metabolic diseases. 

03.08.2017
GMP for EU Pharma

ARS signed a contract with an Austrian company to support in GMP inspection application to the Russian Ministry of Industry and Trade. ARS has also taken responsibilities for variations and renewal.  

31.07.2017
Audit passed

ARS CRO as well as collaborating PK Labs and BE Unit have successfully passed a foreign Sponsor’s audit.